However, some sodium–glucose co-transporter 2 (SGLT2) inhibitors have been shown to be potent suppressors of cardiovascular risks [11, 12], but the effectiveness of SGLT2 inhibitors on suppressing glucose fluctuations in patients with type 2 diabetes mellitus, especially compared with DPP-4 inhibitors, has not been clarified. Here, SLC5A2 is linked to type 2 diabetes mellitus.